Status In progress
Process STA pre-2018
ID number 866

Provisional Schedule

Final appraisal determination 12 October 2018 - 26 October 2018
Expected publication 21 November 2018

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors Steba Biotech
Others Department of Health
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  British Association of Urological Surgeons
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists


Associated public health groups Public Health England
  Public Health Wales
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research
  National Cancer Research Institute


Key events during the development of the guidance:

Date Update
02 August 2018 Committee meeting: 2
02 July 2018 - 23 July 2018 Appraisal consultation: 1
06 June 2018 Committee meeting: 1
03 January 2018 Invitation to participate
13 October 2016 The technology appraisal of padeliporfin for treating localised prostate cancer (ID866) has been delayed at the request of Steba. NICE has agreed to this request because administration of the padeliporfin requires equipment that is currently not available in the NHS. NICE and Steba are exploring how this can be addressed.
02 June 2016 Draft scope documents
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance